KDR antibody - N-terminal region
| Product name: | KDR antibody - N-terminal region |
| Source: | Rabbit |
| Purity: | >95% |
| Buffer Formulation: | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Applications: | WBIHC |
| Storage: | Aliquot and store at -20°C. Avoid repeated freeze / thaw cycles |
| UOM: | 100ug |
Rabbit anti-KDR polyclonal antibody - N-terminal region
Catalog Number:IC122039
Product Profile
| ProductName | Rabbit anti-KDR polyclonal antibody - N-terminal region |
|---|---|
| AntibodyType | Primary Antibodies |
| Immunogen |
The immunogen for anti-KDR antibody: synthetic peptide directed towards the N terminal of human KDR |
Key Feature
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | |
| Species Reactivity | |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
Target Information
| Gene Symbol | KDR |
|---|---|
| Gene Synonyms |
CD309
More
FLK1 VEGFR VEGFR2 |
| Gene Full Name | Kinase insert domain receptor (a type III receptor tyrosine kinase) |
| Gene Summary |
KDR is the receptor for VEGF or VEGFC. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
More
|
| Alternative Names |
CD309
More
FLK1 VEGFR VEGFR2 |
| MolecularWeight(MW) | 151kDa |
| Sequence | 1356 amino acids |
Database Links
| Entrez Gene | 3791 |
|---|---|
| SwissProt ID | P35968 |
| Protein Accession | NP_002244 |
Application
Additional Information
| Form | Liquid |
|---|---|
| Storage Instructions | Aliquot and store at -20°C. Avoid repeated freeze / thaw cycles |
| Storage Buffer | phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
Note: The product is for research use only,not for use in diagnostic or therapeutic procedures.












